Treatment for Lung Squamous Cell Carcinoma
For advanced lung squamous cell carcinoma, first-line treatment should be pembrolizumab or cemiplimab monotherapy if PD-L1 TPS ≥50%, or pembrolizumab/cemiplimab plus carboplatin and paclitaxel (or nab-paclitaxel) if PD-L1 is 1-49% or <1%. 1
First-Line Treatment Algorithm by PD-L1 Expression
PD-L1 TPS ≥50% (Strong Recommendation)
- Preferred: Single-agent pembrolizumab, cemiplimab, or atezolizumab 1
- Alternative options (weaker evidence):
The most recent network meta-analysis (2026) confirms that paclitaxel-based doublet chemotherapy combined with PD-(L)1 inhibitors ranks highest for PFS (SUCRA: 96.52%) and third for OS (SUCRA: 83.58%) 2, supporting the combination approach even in high PD-L1 expressors when maximum efficacy is prioritized.
PD-L1 TPS 1-49% (Strong Recommendation)
- Preferred: Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel OR cemiplimab + carboplatin + paclitaxel 1
- Alternative options:
PD-L1 TPS <1% or Unknown
- Preferred: Pembrolizumab + carboplatin + paclitaxel/nab-paclitaxel OR cemiplimab + carboplatin + paclitaxel 1
- Alternative options: Same as PD-L1 1-49% group 1
Performance Status Considerations
Good Performance Status (PS 0-1)
Follow the PD-L1-stratified algorithm above. The 2018 guideline emphasizes platinum doublet chemotherapy as the backbone, with necitumumab + gemcitabine-cisplatin as an option 3. However, the 2025 ASCO guideline supersedes this, prioritizing immunotherapy combinations 1.
Poor Performance Status (PS 2)
- Non-platinum doublet or single-agent chemotherapy 3
- Consider docetaxel or erlotinib (in EGFR-expressing tumors in Europe; EGFR-mutated in US) 3
- Best supportive care if comorbidities preclude systemic therapy 3
Second-Line Treatment After Immunotherapy Progression
This represents a critical unmet need, as immunotherapy has moved to first-line, leaving limited prospective data for subsequent therapy 4.
Options include:
- Ramucirumab + docetaxel: Real-world data suggest this warrants evaluation post-immunotherapy 4
- Afatinib: Approved second-line after platinum-based chemotherapy; oral administration with defined tolerability profile 4
- Docetaxel monotherapy 3
- Gemcitabine or platinum rechallenge (selected patients) 4
Critical Pitfalls and Caveats
Avoid pemetrexed-based regimens – these are contraindicated in squamous histology and associated with inferior outcomes 3.
Test for rare actionable mutations: While uncommon in squamous cell carcinoma, EGFR mutations can occur. If positive, genotypically-driven therapy should be pursued ahead of chemotherapy or immunotherapy 3.
Central tumor location: Squamous tumors typically arise in proximal bronchi and may invade large vessels, increasing bleeding risk with bevacizumab. Use caution with anti-angiogenic agents 3.
Comorbidities matter: Squamous cell carcinoma patients have higher rates of COPD and cardiovascular disease, which impact treatment tolerance and selection 3.
Early palliative care integration: Patients should be referred to interdisciplinary palliative care teams early in the disease course, alongside active cancer treatment 1.
Emerging Evidence
The 2026 network meta-analysis identifies paclitaxel-based doublet chemotherapy combined with PD-(L)1 inhibitors as having the best balance of PFS benefit (SUCRA: 96.52%) and ORR (SUCRA: 87.00%) 2. Novel approaches under investigation include multi-specific antibodies, antibody-drug conjugates, adoptive cell therapies, and cancer vaccines 5, though these remain investigational.